miR-98 Modulates Cytokine Production from Human PBMCs in Systemic Lupus Erythematosus by Targeting IL-6 mRNA

Table 2

Comparison of demographic and clinical characteristics between SLE patients with and without miR-98 low expression.

	Patients with miR-98 low expression ()	Patients without miR-98 low expression ()
Female, (%)	17 (81.0)	20 (100.0)	0.126
Age at SLE diagnosis, yrs,			0.606
Skin rash, (%)	6 (28.6)	10 (50.0)	0.160
Oral ulcer, (%)	7 (33.3)	9 (45.0)	0.401
Arthritis, (%)	16 (28.6)	10 (50.0)	0.001
Polyserositis, (%)	4 (19.0)	3 (15.0)	0.732
Lupus nephritis, (%)	14(66.7)	6 (30.0)	0.019
Central nervous system involvement, (%)	4 (19.0)	2 (10.0)	0.706
SCr (μmol/L),			0.093
ALB (g/L),			0.120
Complement 3 (g/L),			0.133
IgG (g/L),			0.154
ACL (IgM/IgG), (%)	1 (4.8)	1 (5.0)	0.938
Anti-β2-GP1 (IgG), (%)	2 (9.5)	1 (5.0)	0.720
ANA, (%)	19 (90.5)	19 (95.0)	0.593
Anti-ds-DNA, (%)	13 (61.9)	3 (15.0)	0.004
Anti-Sm, (%)	4 (19.0)	0 (0.0)	0.107
Anti-Ro, (%)	12 (57.1)	7 (35.0)	0.105
Anti-La, (%)	3 (14.3)	1 (5.0)	0.606
Anti-U1RNP, (%)	4 (19.0)	2 (10.0)	0.663
Corticosteroid therapy, (%)	21 (100.0)	19 (95.0)	0.773
IV CYC therapy, (%)	14 (66.7)	9(45.0)	0.577
MMF therapy, (%)	3 (14.3)	2 (10.0)	0.682
Hydroxychloroquine therapy, (%)	19 (90.5)	19 (95.0)	0.593
Disease activity (SLEDAI, )			0.032

Patients with normal and overexpression of miR-98; value < 0.5.